Understanding the causes of PHI-1 up- or downregulation, its underlying mechanisms in tumor progression, and its impact on therapy resistance could uncover novel clinical benefits, including potential biomarkers for prognosis and new targets for cancer treatment. The gene discussed is PPP1R14B; the disease is neoplasm.